Resiquimod
 | |
| Clinical data | |
|---|---|
| Routes of administration | Topical |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
144875-48-9  |
| PubChem (CID) | 159603 |
| IUPHAR/BPS | 5051 |
| ChemSpider |
140330  |
| UNII |
V3DMU7PVXF |
| ChEMBL |
CHEMBL383322 |
| Chemical and physical data | |
| Formula | C17H22N4O2 |
| Molar mass | 314.382 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel[1] in the treatment of skin lesions[2] such as those caused by the herpes simplex virus[3][4] and cutaneous T cell lymphoma,[5] and as an adjuvant to increase the effectiveness of vaccines.[6] It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8,[7] and an upregulator of the opioid growth factor receptor.[8]
See also
References
- ↑ Patents #5, 939, 090 and 6, 365, 166
- ↑ Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC (July 2008). "A phase II dose-ranging study of topical resiquimod to treat actinic keratosis". The British Journal of Dermatology. 159 (1): 205–10. doi:10.1111/j.1365-2133.2008.08615.x. PMID 18476957.
- ↑ Wu JJ, Huang DB, Tyring SK (November 2004). "Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses". Antiviral Research. 64 (2): 79–83. doi:10.1016/j.antiviral.2004.07.002. PMID 15498602.
- ↑ Fife KH, Meng TC, Ferris DG, Liu P (February 2008). "Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions". Antimicrobial Agents and Chemotherapy. 52 (2): 477–82. doi:10.1128/AAC.01173-07. PMC 2224757
. PMID 18039918. - ↑ Rook AH, Gelfand JC, Wysocka M, Troxel AB, Benoit B, Surber C, Elenitsas R, Buchanan MA, Leahy DS, Watanabe R, Kirsch I, Kim EJ, Clark RA (July 30, 2015). "Topical resiquimod can induce disease regression, eradicate malignant T cells and enhance T cell effector functions in cutaneous T cell lymphoma". Blood. American Society of Hematology. doi:10.1182/blood-2015-02-630335.
- ↑ Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP (October 2007). "Resiquimod and other immune response modifiers as vaccine adjuvants". Expert Review of Vaccines. 6 (5): 835–47. doi:10.1586/14760584.6.5.835. PMID 17931162.
- ↑ Hurst J, Prinz N, Lorenz M, Bauer S, Chapman J, Lackner KJ, von Landenberg P (February 2009). "TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells". Immunobiology. 214 (8): 683–91. doi:10.1016/j.imbio.2008.12.003. PMID 19249118.
- ↑ Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ (August 2008). "Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function". Experimental Biology and Medicine (Maywood, N.J.). 233 (8): 968–79. doi:10.3181/0802-RM-58. PMID 18480416.
This article is issued from Wikipedia - version of the 10/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.